Amedisys Reports First Quarter 2022 Financial Results and Reaffirms 2022 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Amedisys (AMED) Tops Q1 EPS by 11c; Offers FY22 Guidance
April 27, 2022 4:10 PM EDTAmedisys (NASDAQ: AMED) reported Q1 EPS of $1.23, $0.11 better than the analyst estimate of $1.12. Revenue for the quarter came in at $545.3 million versus the consensus estimate of $558.84 million.
GUIDANCE:
Amedisys sees FY2022 EPS of $5.23-$5.45, versus the consensus of $5.33. Amedisys sees... More
